Amiodarone Hydrochloride

Phase 3Small molecule

UUniversity of Calgary

Amiodarone Hydrochloride is one of 60 small molecule programs targeting Cardiac Arrest. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac ArrestActive, not recruiting

Atrial FibrillationActive, not recruiting

Chagas CardiomyopathyActive, not recruiting

Cardiac ArrestPhase 3

Active, not recruiting

Atrial FibrillationPreclinical

Active, not recruiting

Chagas CardiomyopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Amiodarone Hydrochloride

UUniversity of Calgary

Phase 3

4 2

Brukinsa

BBeOne Medicines

Preclinical

1 3

Anticoagulants

Sanofi

Preclinical

2 4

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 5

Direct Anticoagulant

Bayer

Preclinical

1 6

Magnesium SO4

HHospital de Base

Preclinical

2 7

Anticoagulation

HHospital Álvaro Cunqueiro

Preclinical

1 8

Medication

NNYU Langone Health

Preclinical

1 9

Bupivacain

IIstanbul University

Preclinical

1 10

Standard BP Control

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Atrial Fibrillation

NCT06067438

Phase 3Recruiting

Cardiac Surgery

NCT05841056

Q1 2028

Phase 3Recruiting

Cardiac Arrest

NCT06680869

Q2 2028

Post-ApprovalRecruiting

Atrial Fibrillation

NCT07273994

Clinical

Trials by Indication[1]

Atrial Fibrillation4 trials

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT06067438·90 enrolled

Oral Amiodarone for Acute Cardioversion of Atrial Fibrillation Study

Terminated·UUniversity of Calgary·Phase 4·NCT04594746·3 enrolled

Catgut Embedding in Acupoints on Treating Persistent Atrial Fibrillation After Catheter Ablation

Unknown status·SShanghai Chest Hospital·N/A·NCT05125042·120 enrolled

Show 1 more trial

Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation

Recruiting·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 4·NCT07273994·312 enrolled

Trial1 trial

A Trial Testing Amiodarone in Chagas Cardiomiopathy

Unknown status·FFundación Cardioinfantil Instituto de Cardiología·Phase 3·NCT03193749·200 enrolled

Chagas cardiomyopathy1 trial

Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death

Unknown status·IInCor Heart Institute·N/A·NCT01722942·1,100 enrolled

Cardiac Surgery1 trial

Short Term Anti-aRrhythmic Therapy for Post-Operative AF in Cardiac Surgery Patients Pilot Trial

Recruiting·PPopulation Health Research Institute·Phase 3·NCT05841056·400 enrolled

Interaction1 trial

Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects

Not yet recruiting·JJemincare·Phase 1·NCT07181265·48 enrolled

1 more indication

Cardiac Arrest1 trial

Early Amiodarone in Shockable Cardiac Arrest

Recruiting·OOregon Health and Science University·Phase 3·NCT06680869·585 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Amiodarone Hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amiodarone Hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amiodarone Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Calgary

Amiodarone Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q1 2028

Q2 2028

Trials by Indication[1]

Atrial Fibrillation4 trials

Trial1 trial

Chagas cardiomyopathy1 trial

Cardiac Surgery1 trial

Interaction1 trial

Cardiac Arrest1 trial

References

Drug Info

Quick Facts

Related News